

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Department of the Army Walter Reed Army Medical Center (WRAMC)</p> <p>2. Washington, D.C. 20307-5001</p>	<p>In accordance with the letter dated May 12, 1998,</p> <p>3. License number 08-01738-02 is amended in its entirety to read as follows:</p> <p>4. Expiration date June 30, 2004</p> <p>5. Docket No. 030-01317 Reference No.</p>
--	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material with atomic numbers 1-83	A. Any	A. 400 millicuries of each radionuclide with a total possession limit of 26 curies
B. Iodine 131	B. Any	B. 2 curies
C. Xenon 133	C. Any	C. 2 curies
D. Krypton 85	D. Any	D. 1 curie
E. Phosphorus 32	E. Any	E. 2 curies
F. Carbon 14	F. Any	F. 2 curies
G. Iodine 125	G. Any	G. 1 curie
H. Iridium 192	H. Any	H. [ ]
I. Chromium 51	I. Any	I. 750 millicuries
J. Sulfur 35	J. Any	J. 1 curie
K. Hydrogen 3	K. Any	K. 5 curies
L. Molybdenum 99	L. Molybdenum 99/ Technetium 99m Generators	L. 23 curies
M. Technetium 99m	M. Any	M. 23 curies
N. Strontium 90	N. Sealed sources	N. [ ]

Information in this record was deleted in accordance with the Freedom of Information Act, exemptions 2 & 6  
FOIA 2006-0238

92



3/1  
KK/m

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number  
08-01738-02

Docket or Reference Number  
030-01317

Amendment No. 71

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
O. Cesium 137	O. Sealed sources	O. 
P. Gadolinium 153	P. Sealed sources	P.
Q. Iodine 125	Q. Sealed sources (3M Company seeds)	Q. 1 curie
R. Iodine 125	R. Sealed sources (Norland Inst. Co., Model 178A591A or AECL Models C235 or C324, or Amersham Corp. Model-IMC.P2)	R. 4 sources, not to exceed 300 millicuries each
S. Cesium 137	S. Sealed sources	S. 
T. Cobalt 60	T. Sealed sources	T.
U. Americium 241	U. Any	U. 100 microcuries
V. Americium 241	V. Sealed sources (Monsanto Model NRC-2704)	V.
W. Nickel 63	W. Sealed sources and foils	W. 1 curie
X. Iodine 129	X. Sealed sources	X. 1 curie
Y. Thorium	Y. Any	Y. 5 kilograms
Z. Uranium	Z. Any	Z. 50 kilograms
AA. Cesium 137	AA. Sealed sources	AA. 
BB. Americium 241	BB. Sealed sources	BB. s
CC. Cesium 137	CC. Sealed source	CC.
DD. Paladium 103	DD. Sealed sources	DD. 3 curies
EE. Uranium depleted in Uranium 235	EE. Plated Metal	EE. 400 Kilograms

Ex 2

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
08-01738-02

Docket or Reference Number  
030-01317

Amendment No. 71

9. Authorized use:

- A. through DD. Medical diagnosis, therapy and research in humans in accordance with any applicable Food and Drug Administration (FDA) requirements. Research and development as defined in 10 CFR 30.4, including animal studies; instrument calibration; student instruction.
- EE. Shielding in linear accelerators.

CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at the Walter Reed Army Medical Center, Washington, D. C.; WRAMC Forest Glen Section and Annex, Silver Spring, Maryland; U.S. Army Medical Laboratory, WRAMC Department of Pathology, Fort Meade, Maryland; Rickman Building, 13 Taft Court, Rockville, Maryland and Gillette Building, 270 Research Center, 1413 Research Boulevard, Rockville, Maryland.
11. A. Licensed material shall be used by, or under the supervision of, individuals designated in writing by the Radiation Safety Committee, Colonel Yancy Phillips, Chairperson.
- B. The use of licensed material in or on humans shall be by a physician, dentist, or podiatrist as defined in 10 CFR 35.2.
- C. Physicians, dentists, or podiatrists designated to use licensed material in or on humans shall meet the training criteria established in 10 CFR 35, Subpart J and shall be designated in writing by the licensee's Radiation Safety Committee.
- D. The Radiation Safety Officer for this license is Colonel William B. Johnson.
12. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
13. Notwithstanding the requirements of 10 CFR 35.49(a) and (b), 35.100, 35.200, 35.300, 35.400 and 35.500 the licensee may use for any medical use any byproduct material or reagent kit. The licensee shall possess and use byproduct material for medical use in accordance with the prescriptive and performance criteria in the other sections of 10 CFR 35. This does not relieve the licensee from complying with applicable U.S. Food and Drug Administration (FDA) and other Federal and State requirements.
14. A. Detector cells containing a titanium tritide foil or a scandium tritide foil shall only be used in conjunction with a properly operating temperature control mechanism which prevents the foil temperatures from exceeding that specified in the certificate of registration referred to in 10 CFR 32.210.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
08-01738-02Docket or Reference Number  
030-01317

Amendment No. 71

- B. When in use, detector cells containing a titanium tritide foil or a scandium tritide foil shall be vented to the outside.
15. The licensee shall conduct a physical inventory every three months to account for all sealed sources and devices containing licensed material received and possessed pursuant to 10 CFR 35.59, 35.400 and 35.500 and every six months for all other sealed sources and devices.
16. A. Sealed sources and detector cells containing licensed material shall be tested for leakage and/or contamination at intervals not to exceed six months or at such other intervals as are specified by the certificate of registration referred to in 10 CFR 32.210, not to exceed three years.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed three months.
- C. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.
- D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.
- E. Sealed sources and detector cells need not be leak tested if:
- (i) they contain only hydrogen-3; or
  - (ii) they contain only a radioactive gas; or
  - (iii) the half-life of the isotope is 30 days or less; or
  - (iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or
  - (v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transfer to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- F. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source or detector cell shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within five days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety Branch, 475 Allendale Road, King of Prussia, Pennsylvania 19406. The

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
08-01738-02Docket or Reference Number  
030-01317

Amendment No. 71


report shall specify the source or detector cell involved, the test results, and corrective action taken.

- G. The licensee is authorized to collect leak test samples for analysis by the licensee. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.
17. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
18. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days and Sulfur 35, Cobalt 58, Iridium 192, Scandium 46, for decay-in-storage before disposal in ordinary trash, provided:
- A. Waste to be disposed of in this manner shall be held for decay a minimum of ten half-lives.
  - B. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.
  - C. A record of each such disposal permitted under this License Condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.
19. Experimental animals, or the products from experimental animals, that have been administered licensed materials shall not be used for human consumption.
20. The licensee shall possess and use byproduct material for human research in accordance with the prescriptive and performance criteria in all sections of 10 CFR Part 35 except sections 35.49(a) and (b), 35.100, 35.200, and 35.300.
21. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
22. The licensee shall not acquire licensed material in a sealed source or device unless the source or device has been registered with the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or equivalent regulations of an Agreement State.
23. Radioactive waste generated shall be stored in accordance with the statements, representations, and procedures included with the waste storage plan described in the licensee's letter/application dated September 9, 1993 and October 29, 1993.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
08-01738-02Docket or Reference Number  
030-01317

Amendment No. 71

24. Notwithstanding the requirements of 10 CFR 35.315(a)(7), the licensee may control contamination in rooms used to house radiopharmaceutical therapy patients in accordance with the commitments and procedures contained in the letters dated April 8, 1992 and November 24, 1992.
25. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 21, 1993
  - B. Letter dated September 9, 1993
  - C. Letter dated October 29, 1993
  - D. Letter dated December 9, 1993
  - E. Letter dated February 15, 1994
  - F. Letter dated June 2, 1994
  - G. Letter dated December 6, 1996



For the U.S. Nuclear Regulatory Commission

Date June 9, 1998

By

*Original signed by Michelle Beardsley*Michelle Beardsley  
Nuclear Materials Safety Branch 1  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406

June 9, 1998

Docket No. 030-01317  
Control No. 125704

License No. 08-01738-02

William B. Johnson  
Colonel, U.S. Army  
Radiation Protection Officer  
Department of the Army  
Walter Reed Army Medical Center (WRAMC)  
MCHL-HP/Health Physics Office  
Building 41, Room 38  
Washington, D.C. 20307-5001

Dear Colonel Johnson:

This refers to your license amendment request. Enclosed with this letter is the amended license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5093 or 5239, so that we can provide appropriate corrections and answers.

Thank you for your cooperation.

Sincerely,

***Original signed by Michelle Beardsley***

Michelle Beardsley  
Health Physicist  
Nuclear Materials Safety Branch 1  
Division of Nuclear Materials Safety

Enclosure:  
Amendment No. 71

cc:  
Col. Eric Daxon, U.S. Army Medical Command

ML10

W. Johnson  
Radiation Protection Officer

2

DOCUMENT NAME: G:\DNMS\DOCWORK\LICLTR\0801738.02

16911863

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI				
NAME	MBeardsley <i>MB</i>						
DATE	06/09/98		06/ /98		06/ /98		06/ /98

OFFICIAL RECORD COPY



DEPARTMENT OF THE ARMY  
WALTER REED ARMY MEDICAL CENTER  
WALTER REED HEALTH CARE SYSTEM  
WASHINGTON, DC 20307-5001

REPLY TO  
ATTENTION OF

May 12, 1998

Preventive Medicine Services

Nuclear Regulatory Commission, Region I  
Medical Licensing Division  
475 Alendale Road  
King of Prussia, Pennsylvania 19406-1415

Dear Sir or Madam:

Walter Reed Army Medical Center (WRAMC) uses radioactive material authorized by U.S. Nuclear Regulatory Commission (NRC) Byproduct Material License number 08-01738-02 with an expiration date of June 30, 2004. This is a medical broadscope Type A license for medical diagnosis, therapy, and research in humans in accordance with any applicable Food and Drug Administration (FDA) requirements. Research and development as defined in 10 CFR 30.4, including animal studies; instrument calibration; and student instruction.

We request to amend NRC License 08-01738-02 issued to Walter Reed Army Medical Center (WRAMC), Washington, DC to appoint Colonel Yancy Phillips, replacing Colonel John R. Pierce, Deputy Commander for Clinical Services (DCCS), as the Chairman of the Radiation Control Committee (RCC). As the DCCS, Colonel Phillips is in a senior level executive management position, one level below the Hospital Commander, WRAMC. The Radiation Protection Officer, Colonel William B. Johnson has carefully reviewed the curriculum vitae (enclosure) and has recommended Colonel Phillips approval as Chairman of the RCC.

For additional information, please contact the undersigned at (202) 356-0058.

Sincerely,

  
William B. Johnson  
Colonel, U.S. Army  
Radiation Protection Officer

Enclosure

Copy Furnished:

Headquarters, U.S. Army Medical Command, ATTN: MCHO-CL-W (Colonel Daxon), 2050  
Worth Road, Ft. Sam Houston, TX 78234-6000

1 2 5 7 0 4

OFFICIAL RECORD COPY ML 10

MAY 19 1998

CURRICULUM VITAE

March 1998

NAME: Yancy Y Phillips, III

SSAN:

[Redacted]

RANK: Colonel, Medical Corps

MOS: 60F9A

DOB:

[Redacted]

POB:

SPOUSE:

CHILDREN:

HOME ADDRESS:

Ex. 6

WORK ADDRESS: Department of Medicine  
Walter Reed Army Medical Center  
Washington, DC 20307-5001  
202-782-6205/2348  
FAX 202-782-6507  
E-Mail: COL\_YANCY\_PHILLIPS@WRAMC1-AMEDD.ARMY.MIL

EDUCATION:

1971 BS Chemical Engineering (High Honors), University of Delaware

1974 Master of Medical Science, CMDNJ-Rutgers Medical School

1976 Doctor of Medicine (Cum Laude), University of Alabama School of Medicine

POST-GRADUATE EDUCATION:

1976-77 Internal Medicine Internship, Tripler Army Med Center, Honolulu, HI

1977-79 Internal Medicine Residency, Tripler Army Medical Center

1980-83 Pulmonary Medicine Fellowship, Walter Reed Army Medical Center  
Washington, D.C.

## ACADEMIC APPOINTMENTS:

- 1983-90 Assistant Professor of Medicine, Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD
- 1989-93 Program Director, Pulmonary Disease Fellowship, WRAMC
- 1990- Associate Professor of Medicine, USUHS
- 1993- Director, Internal Medicine Residency, WRAMC
- 1993- Associate Chairman, Department of Medicine, USUHS

## CLINICAL AND PROFESSIONAL POSITIONS:

- 1971-72 Chemical Engineer, Exxon Corporation, Linden, NJ
- 1979-80 Internist and Chief, CCU, Dewitt Army Hospital, Ft Belvoir, VA
- 1980-82 Program Manager, Blast Overpressure Project, Non-Auditory, Walter Reed Army Institute of Research, Washington, D.C.
- 1983-87 Chief, Department of Respiratory Research, Walter Reed Army Institute of Research
- 1987-89 Director, Medical Intensive Care Unit, Walter Reed Army Medical Center (WRAMC)
- 1989-90 Chief, Pulmonary Disease Service, WRAMC
- 1990-93 Chief, Pulmonary & Critical Care Medicine Service, WRAMC
- 1993- Chief, Department of Medicine, WRAMC

## SELECTED COMMITTEE POSITIONS AND CONSULTANCIES

- 1981-87 US Delegate, NATO Panel VIII, Research Study Group 6
- 1990-93 Pulmonary Consultant to the Surgeon General of the Army
- 1990-93 Respiratory Therapy Consultant to the Surgeon General of the Army
- 1992-95 Chairman, Mobilization and Readiness Committee, WRAMC

- 1993- Chairman, CQI Performance Improvement Council, WRAMC
- 1994- Chairman, Army Region American College of Physicians      Annual Meeting
- 1994- NIH, National Heart, Lung and Blood Institute (NHLBI)      Advisory Council
- 1994-96      NHLBI, Lung Division, Workshop on Planning a National Strategy for  
Chronic Obstructive Pulmonary Disease
- 1994- NHLBI, Lung Division, Data and Safety Monitoring Board for  
Lung Health Study 2
- 1997- DOD(HA) Working Group on Computerized Patient Record
- 1997    NHLBI and FDA sponsored Workshop on Pulmonary Artery Catheterization and  
Clinical Outcomes
- 1997- Pre-reviewer for Pulmonary and Critical Care Medicine fellowships for  
Accreditation Council for Graduate Medical Education (ACGME)

#### HONORS AND AWARDS:

- Omicron Delta Kappa Honor Society, Univ of Del, 1970
- Alpha Omega Alpha, Univ of Alabama, 1975
- Dean's Honor Award, UAH, 1976
- Resident's Award for Outstanding Research, TAMC, 1979
- Fellow, American College of Chest Physicians, 1987
- Fellow, American College of Physicians, 1993
- Chennault Award for Outstanding Teacher, WRAMC, 1993

#### BOARD CERTIFICATIONS:

- Diplomate, National Board of Medical Examiners, 1977
- Diplomate #72508, American Board of Internal Medicine, 1979
- Diplomate in Pulmonary Disease, ABIM, 1984
- Diplomate in Critical Care Medicine, ABIM, 1991
- Diplomate of American Board Of Medical Management, 1996

#### MEDICAL LICENSE:

- Virginia 1979 to present, #11-030980
- Louisiana 1985, #06724R
- DEA Number AP9479191

## PROFESSIONAL SOCIETIES:

American College of Chest Physicians, Fellow, 1987-present  
Governor for US Army, 1992-95  
American College of Physicians, Fellow, 1990-present  
American College of Physician Executives, Member, 1993- present  
American Thoracic Society, 1987-present  
Chairman, Long Range Planning Committee of Clinical Problems  
Assembly, 1991-95  
Member, Health Care Policy and Clinical Practice Committee, 1993-95  
Member, Clinical Practice Committee, 1995-97  
Writing Committee, Statement on "Evaluation and Care of the Patient with  
COPD", 1993-95  
Association of Military Surgeons of US, 1981-present  
Association of Program Directors of Internal Medicine, 1993-  
Curriculum Review Ad Hoc Committee, 1996  
Association of Pulmonary and Critical Care Medicine Program  
Directors, 1990-1993  
District of Columbia Thoracic Society, 1987-1994  
Executive Committee, 1989-1993  
Co-Chairman American Lung Association of DC Research Committee  
1992 & 1993

## EDITORIAL REVIEWER:

New England Journal of Medicine  
American Journal of Respiratory and Critical Care Medicine  
Chest  
Pediatric Pulmonology  
Journal of Respiratory Diseases  
American Medical Association panel member for Diagnostic and Therapeutic  
Technology Assessment  
ABIM Pulmonary Disease Re-Certification, question preparation

**MILITARY AWARDS:**

Department of the Army Research and Development Achievement  
Award for 1988

Meritorious Service Medal with 4 Oak Leaf Clusters

Army Commendation Medal with 1 Oak Leaf Cluster

Army Achievement Medal with 1 Oak Leaf Cluster

Army Superior Unit Award (2)

"A" Proficiency Designator for AOC 60F (Pulmonary Disease)

Order of Military Medical Merit

**MILITARY EDUCATION:**

AMEDD Officers Basic Course (Constructive Credit), 1979

AMEDD Officers Advanced Course (Constructive Credit), 1982

Combat Casualty Care Course (C4A), 1986

Armed Forces Staff College (In Residence), 1989

Medical Management of Chemical Casualties Course, 1990

## PUBLICATIONS:

1. Laughlin E, Dorosin N, Phillips Y. Total parenteral nutrition: a guide to therapy in the adult. *J Fam Pract* 1977; 5:947.
2. Phillips YY, Lonigan M, Joyner L. A simple technique for managing a bronchopleural fistula while maintaining positive pressure ventilation. *Crit Care Med* 1979; 7:351.
3. Phillips YY, Copley JB, Stor RA. Thrombocytopenia and low dose heparin. *Southern Med J* 1983; 76:526.
4. Verma PS, Hoyt RF, Jackson AJ, Phillips YY. Pharmacokinetics of intravenously administered desmosine in sheep. *Conn Tissue Res* 1984; 12:191.
5. Young AJ, Jaeger JJ, Phillips YY, Yelverton JT, Richmond DR. The influence of airway pressure on lung injury resulting from airblast. *Military Medicine* 1985; 150:31-33.
6. Young AJ, Jaeger JJ, Phillips YY, Yelverton JT, Richmond DR. The influence of clothing on human intrathoracic pressure during airblast. *Aviat Space Environ Med* 1985; 56:49-53.
7. Phillips YY, Jaeger JJ, Laube BL, Rosenthal RR. Eucapnic hyperventilation of compressed gas mixture: a simple system for bronchial challenge by respiratory heat loss. *Am Rev Respir Dis* 1985; 131:31-35.
8. Young AJ, Jaeger JJ, Phillips YY, Fletcher ER and Richmond DR. Intrathoracic pressure in humans exposed to short duration airblast. *Mil Med* 1985; 150:483-6.
9. Young AJ, Hoyt RF, Jaeger JJ, Phillips YY, Richmond DR. Short duration airblast does not increase pulmonary microvascular permeability. *Military Medicine* 1986; 151, 3:139-143.
10. Hoyt RF, Hayre MD, Dodd KT, Phillips YY. Long-acting intramuscular anesthetic Regimen for swine. *Lab Animal Science* 1986; 36:413-15.
11. Phillips YY. Primary blast injuries. *Annals of Emergency Medicine* 1986; 15:1446-1450.
12. Stuhmiller JH, Chuong CJ, Dodd KT, Phillips YY. Computer modeling of thoracic response to blast. *Journal of Trauma* 1988; 28:S132-9.
13. Phillips YY, Mundie TG, Yelverton JT, Richmond DR. Cloth ballistic vest alters response to blast. *Journal of Trauma* 1988; 28:S149-52.

14. Harmon JW, Sampson JQ, Graeber GM, Phillips YY. Readily available serum biochemical markers fail to aid in diagnosis of blast injury. *Journal of Trauma* 1988; 28:S153-S159.
15. Phillips YY and Patterson JH. Protection against noise and blast. *Medical Bulletin of the US Army Medical Department*, PB 8-88-2, Feb 1988.
16. O'Hair KC, Dodd KT, Phillips YY, Beattie RJ. Cardiopulmonary effects of nalbuphine hydrochloride and butorphanol tartrate in sheep. *Lab Animal Sciences* 1988; 38:58-60.
17. Mundie TG, Pamplin CL, Phillips YY, Smallridge RC. The effect of exercise in sheep on the absorption of intramuscular atropine sulfate. *Pharmacology* 1988; 37:132-136.
18. McNeil JS, Torrington KG, Mundie TG, Ripple GR, Phillips YY. A steady state method of measuring carbon monoxide diffusing capacity of the lung of sheep. *Lab Anim Sci* 1989; 39:33-36.
19. Phillips YY, Mundie TG, Dodd KT. Middle ear injuries in animals exposed to complex blast waves inside an armored vehicle. *Annals of Otology, Rhinology & Laryngology*. 1989; 98(5,2):17-22.
20. Richmond DR, Yelverton JT, Fletcher ER, Phillips YY. Physical correlates of eardrum rupture. *Annals of Otology, Rhinology & Laryngology*. 1989; 98(5,2): 35-41.
21. Phillips YY and Zatzchuk JT. Blast injuries of the ear in military operations. *Annals of Otology, Rhinology & Laryngology*. 1989; 98(5,2):3-4.
22. Rayburn DB, Mundie TG, Rosenthal RR, Phillips YY. Computer controlled large animal pulmonary function system. *Computer Methods and Programs in Biomedicine* 1989; 28:1-9.
23. Phillips, YY; Ripple, GR; Dodd, KT; and Mundie, TG. Medical evaluation of live fire test injuries. *Army Research, Development & Acquisition Bulletin* Nov-Dec 1989:16-18.
24. Eliasson AE, Tenholder MF, Phillips YY. Treatment of lymphangiomyomatosis- a meta-analysis. *Chest* 1989; 196:1352-55.
25. Torrington KG, McNeil JS, Phillips YY, Ripple GR. Blood volume determination in sheep before and after splenectomy. *Laboratory Animal Science* 1989; 39:598-602.

26. Ripple GR, Torrington KG, Phillips YY. Predictive criteria for burns from brief thermal exposures. *J Occup Med* 1990; 32:215-9.
27. Duffy PE and Phillips YY. Caffeine consumption decreases the response to bronchoprovocation challenge with dry gas hyperventilation. *Chest* 1991; 99:1374-77.
28. McNeil JS, Torrington KG, Mundie TG, Ripple GR, Phillips YY, Banks RA. Prediction of carbon monoxide diffusing capacity of the lung in splenectomized sheep, *Lab Animal Sci* 1991, 41:63-66.
29. Tenholder MF, Rajagopal KR, Phillips YY, Dillard TA, et.al. Urinary desmosine excretion as a marker of lung injury in the adult respiratory distress syndrome. *Chest* 1991; 100:1385-1390.
30. Yu JH, Vassel EJ, Hoyt RF, Phillips YY, Dodd KT. Autologous perfusion of an isolated rabbit gastrointestinal tract. *Lab Animal Sci* 1991; 41:66-70.
31. Poropatich R and Phillips YY. Listeria brain abscess in long-standing sarcoidosis. *Southern Med J* 1992; 85:554-556.
32. Eliasson AE, Phillips YY, Rajagopal KR, Howard RS. Sensitivity and specificity of bronchial provocation testing. An evaluation of four techniques in exercise-induced bronchospasm. *Chest* 1992; 102:347-355.
33. Eliasson AE, Phillips YY, et. al. Oxygen consumption and ventilation during normal labor. *Chest* 1992; 102:467-471.
34. Landry FJ, Parker JM, Phillips YY. "Outcome of cardiopulmonary resuscitation in the intensive care setting". *Arch Int Med* 1992; 152:2305-2308.
35. Argyros GJ, Phillips YY, Rayburn DB, Rosenthal RR, Jaeger JJ. Water loss without heat flux in exercise-induced bronchospasm. *Am Rev Resp Dis* 1993; 147:1419-1424.
36. Roach JM, Eliasson AH, Phillips YY. The effect of pyridostigmine on bronchial hyper-reactivity. *Chest* 1993; 103:1755-58.
37. Parker JM, Landry FJ, Phillips YY. Use of do-not-resuscitate orders in an intensive care setting. *Chest* 1993; 104:1592-96.
38. Roach JM, Argyros GJ, Hurwitz KM, Argyros GJ, Eliasson AH, Phillips YY. Eucapnic voluntary hyperventilation as a bronchoprovocation technique: comparison with methacholine inhalation in asthmatics. *Chest* 1994; 105:667-672.

39. Hurwitz KM, Roach J, Argyros G, Eliasson AH, Phillips YY. Refractory period after during provocation with eucapnic hyperventilation and methacholine. *Am J Resp Crit Care Med* 1994; 149:1452-6.
40. Parker JM, Torrington KT, Phillips YY. Chylothorax in sarcoidosis. *South Med J* 1994; 87:860-2.
41. Parker JM, Dillard TA, Phillips YY. Impact of using stated versus measured height on screening spirometry. *Am J Resp Crit Care Med* 1994; 150:1705-8.
42. Dillard TA, Moores LK, Bilello KL and Phillips YY. The pre-flight evaluation: a comparison of the hypoxic inhalation test with hypobaric exposure. *Chest* 1995; 107:352-7.
43. Phillips YY. The development of practice guidelines in pulmonary medicine. *Clin Pulm Med* 1995; 2:224-230.
44. Argyros GJ, Roach JM, Hurwitz KM, Eliasson AH and Phillips YY. The refractory period after eucapnic voluntary hyperventilation challenge and it's effect on challenge technique. *Chest* 1995; 108:419-424.
45. Hurwitz KM, Argyros GJ, Roach JM, Eliasson AE, Phillips YY. Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma. *Chest* 1995; 108:1240-1245.
46. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1995; 152:S77-S120.
47. Knutson SW, Dillard TA, Mehm WJ, Phillips YY. Effect of upright and supine posture on hypoxemia during air transport. *Aviat Space Envir Med* 1996; Jan:14-18.
48. Glass KL, Dillard TA, Phillips YY, Torrington KG. Pulse oximetry correction for smoking exposure. *Mil Med* 1996; 161:273-276.
49. Argyros GJ, Phillips YY, Eliasson AE, Roach JM, Hurwitz K. Eucapnic voluntary hyperventilation as a bronchoprovocation technique: development of a standardized ventilatory dosing schedule in asthmatics. *Chest* 1996; 109:1520-1524.
50. Parker JM, Dillard TA, Phillips YY. Arm span:height relationships in a population of patients referred for spirometry. *Am J Resp Crit Care Med* 1996; 154:533-6.
51. Kim H, Lepler L, Daniels A, Phillips Y. Alpha 1-antitrypsin deficinecy and idiopathic pulmonary fibrosis in a family. *South Med J* 1996; 89:1008-10.

52. Eliasson AH, Howard RS, Torrington KG, Dillard TA, Phillips YY. Do-not resuscitate decisions in the medical ICU; comparing physician and nurse opinions. *Chest* 1997; 111:1106-11.
53. Argyros G, Pike J, Phillips YY. Bronchodilator therapy prior to elective fiberoptic bronchoscopy: an evaluation of ipratropium bromide and metaproterenol sulfate dispensed by metered dose inhaler. *J of Bronchology* 1997; 4:106-110.
54. Petty TL and Weinmann. Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease--National Heart, Lung, and Blood Institute workshop summary. (section leader and author) *JAMA*, 1997; 277:246-253.
55. Heffner JE, Aitken M, Geist L, Osborne, Phillips YY, Strohl K. Attributes of ATS documents that guide clinical practice--recommendations of the ATS Clinical Practice Committee. *Am J Resp Crit Care Med* (accepted for publication)
56. Phillips YY and Hnatiuk OW. Diagnosing and monitoring the clinical course of COPD. *Resp Care Clinics NA*. (Invited paper submitted)
57. Phillips YY, Kristo D, Kallish M. Writing the take-home prescription for oxygen for hospitalized COPD patients. *J of Critical Illness* 1998 13:112-22.
58. Moores LK, Rayburn DB, Phillips YY and Fitzpatrick TM. Utilization of capnography as a non-volitional means of estimating airway obstruction. (submitted)
59. Shorr AF, Niven AS, Howard RS, Phillips YY. The American College of Physicians resident abstract competition: success of U.S. military trainees. (submitted)

## BOOK CHAPTERS

1. Phillips YY, Dancer A, Richmond DR. Nonauditory effects of repeated exposure to intense impulse noise; in: Applied and Basic Aspects of Noise Induced Hearing Loss. Salvi R, et al, ed. Plenum Publishing, 1986.
2. Phillips YY and Graeber GM. Blast Injuries in Emergency War Surgery. Bowen and Bellamy, eds. United States Government Printing Office, Washington, D.C., 1988.
3. Phillips YY and Ripple GR. Primary Blast Injury. in The Clinical Practice of Emergency Medicine, Ed. Harwood-Nuss, J.B. Lippincott Company 1990, Philadelphia.
4. Phillips YY and Richmond DR. Primary Blast Injury and Basic Research: a Brief History. in Conventional Warfare: Ballistic, Blast and Burn Injuries (Textbook of Military Medicine, Part I, Vol 5), Office of the Surgeon General, Department of the Army, 1991, US Government Printing Office, Washington, DC.
5. Stuhmiller JH, Phillips YY and Richmond DR. The Physics and Mechanisms of Primary Blast Injury. in Conventional Warfare: Ballistic, Blast and Burn Injuries (Textbook of Military Medicine, Part I, Vol 5), Office of the Surgeon General, Department of the Army, 1991, US Government Printing Office, Washington, DC.
6. Sharpnack DD, Johnson AJ and Phillips YY. The Pathophysiology of Primary Blast Injury. in Conventional Warfare: Ballistic, Blast and Burn Injuries (Textbook of Military Medicine, Part I, Vol 5), Office of the Surgeon General, Department of the Army, 1991, US Government Printing Office, Washington, DC.
7. Phillips YY and Zajtchuk JT. The Management of Primary Blast Injury. in Conventional Warfare: Ballistic, Blast and Burn Injuries (Textbook of Military Medicine, Part I, Vol 5), Office of the Surgeon General, Department of the Army, 1991, US Government Printing Office, Washington, DC.
8. Phillips YY, Torrington KG, Hnatiuk OW. Chronic Obstructive Pulmonary Disease. in Respiratory Care: a Guide to Clinical Practice, 1997, 4th Edition, Burton, Hodgkin, and Ward Eds, J.B. Lippincott, Philadelphia.
9. Ripple GR and Phillips YY. Military Explosions. in Scientific Foundations of Trauma, Edited by Cooper G, Dudley H, Gann D, Little R and Maynard R. Butterworth Heinemann, 1997, Oxford, England.

## PRESENTATIONS (1993-97)

Scientific posters presented at International Scientific Assembly (American Thoracic Society) May 1993, San Francisco, CA:

Roach JM, Argyros GJ, Hurwitz KM, Eliasson AH, Phillips YY. "Eucapnic voluntary hyperventilation with dry gas as a bronchoprovocation technique in asthmatics: comparison with methacholine"

Hurwitz KM, Roach J, Phillips YY, Argyros G, Eliasson AH. "Analysis of refractory period after sequential testing with eucapnic voluntary hyperventilation and methacholine inhalation challenge"

Parker JM, Dillard TA, Phillips YY. "Impact of using stated versus measured height on screening spirometry"

Eliasson AE, Poropatich RK, Howard RS, Phillips YY. PFT "Parameters in bronchoprovocation tests"

Scientific posters presented at the 59<sup>th</sup> International Scientific Assembly of the American College of Chest Physicians, Orlando, FL, October 1993:

Kumke KM, Derderian SS, Hamm CK, Phillips YY, Rajagopal KR. "The effect of Buspirone on sleep in stable asthmatics with severe air flow obstruction"

Weidner SF, Dillard TA, Barg BW, Mehm WJ, Phillips YY, et al. "Effect of upright and supine posture on hypoxemia during air transport"

Slide presentations at 10<sup>th</sup> Annual Army Scientific/ACP Meeting, Orlando, FL, November 1993:

Parker JM, Dillard TA, Phillips YY. "Impact of stated versus measured height on screening spirometry"

Leppler LS, Argyros G, Phillips YY, Dillard TA, et al. "The utility of capnography and transcutaneous capnometry in the evaluation of airflow obstruction and gas exchange in obstructive lung disease"

Argyros GJ, Phillips YY, Eliasson AE, Roach JM, Hurwitz K. "Eucapnic voluntary hyperventilation as a bronchoprovocation technique: development of a standardized ventilatory dosing schedule in asthmatics"

Kumke KM, Derderian SS, Hamm CK, Phillips YY, Rajagopal KR. "The effect of Buspirone on sleep in stable asthmatics with severe airflow obstruction"

Eliasson AH, Phillips YY, Torrington KG, Howard RS, Taylor YL, Dillard TA. "The Grim Reaper: MD or RN?"

Weidner SF, Dillard TA, Berg BW, Mehm WJ, Phillips YY, Rajagopal KR. "Effect of upright and supine posture on hypoxemia during air transport"

Phillips YY. Exercise-induced asthma and eucapnic voluntary hyperventilation. Pulmonary Grand Rounds, Feb 1994, Brown University, Providence, RI.

Scientific posters presented at the International Scientific Assembly (American Thoracic Society) May 1994, Boston, MA:

Eliasson AH, Phillips YY, Torrington KG, Howard RS, Taylor YL, Dillard TA. "The Grim Reaper: MD or RN?"

Glass KL, Dillard TA, Phillips YY, Torrington KG. "Pulse oximetry correction for smoking exposure"

Kumke KM, Derderian SS, Hamm CK, Phillips YY, Rajagopal KR. "The effect of Buspirone on sleep in stable asthmatics with severe airflow obstruction"

Rayburn DB, Fitzpatrick TM, Lepler LS, Truwit JD and Phillips YY. "Neural network analysis of sequential volume segments from expiratory CO<sub>2</sub> curves in the computation of FEV<sub>1</sub>/FVC ratio and predicted FEV<sub>1</sub>"

Berg BW, Dillard TA, Phillips YY, Weidner SF and Rajagopal KR. "Hypoxia inhalation testing (HIT): application in COPD"

Dillard TA, Moores LK, Bilello KL and Phillips YY. "The pre-flight evaluation: a comparison of the hypoxic inhalation test with hypobaric exposure"

Derderian SS, Dillard TA, Mehm WJ, Phillips YY and Rajagopal KR. "Hemodynamic effects of altitude exposure to subjects with lung disease"

Argyros GJ, Roach JM, Hurwitz KM, Eliasson AH and Phillips YY. "The refractory period after eucapnic voluntary hyperventilation challenge and its effect on challenge technique"

Belman MJ and Phillips YY, Co-Chairs. "Healthcare reform and clinical guidelines: pulmonary medicine in the year 2000". Symposium at International Scientific Assembly (American Thoracic Society) May 1994, Boston, MA.

Phillips YY. "Clinical practice guidelines in the ATS". Podium presentation in Symposium on Healthcare reform and clinical guidelines: pulmonary medicine in the year 2000, at International Scientific Assembly (American Thoracic Society) May 1994, Boston, MA.

Phillips YY. "Staging of COPD". Podium presentation in Symposium on Proposed clinical practice guidelines and standards of care for the patient with COPD, at International Scientific Assembly (American Thoracic Society) May 1994, Boston, MA.

Howe JD, Green DL, Phillips YY. The use of a single patient trial to determine the effectiveness of morphine sulfate or alprazolam in the treatment of dyspnea associated with emphysematous COPD. Tri-Service Pharmacy Conference, San Antonio, TX. 1994.

Phillips YY. "Clinical practice guidelines in respiratory medicine" Invited podium presentation to 23rd Annual Joint Conference of New Jersey Chapters of ATS and ACCP, 10 Mar 95, New Brunswick, NJ.

Scientific posters presented at the International Scientific Assembly (American Thoracic Society) May 1995, Seattle, WA:

Hurwitz KM, Eliasson AH, Argyros GJ, Phillips YY. "Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma".

Argyros GJ, Roach JM, Hurwitz KM, Eliasson AH, Phillips YY. Eucapnic voluntary hyperventilation as a bronchoprovocation technique: development of a standardized ventilatory dosing schedule in asthmatics.

Dillard TA, Knutsen SW, Phillips YY, Berg BW, Mehm WJ, Criswell D. Prevention of altitude hypoxemia: comparison of an oxygen conserving device with nasal cannulae.

Parker JM, Dillard TA, Phillips YY. Arm span to height relationships in patients referred for screening spirometry.

Phillips YY. Practice guidelines: What? Why? and How? Meet the Professor Seminar at the International Scientific Assembly (American Thoracic Society) May 1995, Seattle, WA.

Phillips YY. COPD in the managed care environment. NIH Workshop on "Building a national strategy for prevention, management and research in COPD". Bethesda, MD, 30 Aug 95.

Phillips YY. New ATS COPD Guidelines. Grand Rounds, Sibley Hospital, Chevy Chase, MD, 22 Sep 95.

Phillips YY. "Clinical practice guidelines guidelines: issues and realities (new American Thoracic Society COPD Standards)". USUHS Division of Pharmacology Seminar Series, Bethesda, MD, 12 Oct 95.

Poster presentations at the 61st International Scientific Assembly of the American College of Chest Physicians, New York, NY, October 1995:

Lawless NP, Dillard TA, Torrington KG, Phillips YY. Venturi devices for hypoxia inhalation testing.

Moores LK, Phillips YY, Bilello KM, Dillard TA. The effect of chronic oral diltiazem therapy on exercise capacity and response to hypoxic gas inhalation in severe COPD.

Moores LK, Phillips YY, Bilello KM, Dillard TA. The effect of acute and chronic diltiazem administration on pulmonary gas exchange and oxygen delivery in severe COPD.

Phillips YY. Pulmonary Medicine and Operation Desert Storm. Pulmonary Grand Rounds, University of Pittsburgh, 9 April 1996.

Presentations at International Scientific Assembly (American Thoracic Society) May 1996, New Orleans, LA:

Phillips YY and Anderson S, Co-Chairs. "Clinical Bronchoprovocation Testing" Major Clinical Symposium

Phillips YY. Airway reactivity in non-asthmatic lung diseases. Podium presentation

Phillips YY. ATS Statements and Guidelines. Session in Pre-Course

Dillard TA, Knutson SW, Berg BW, Mehm WJ, Phillips YY. Accuracy of formulae for predicting hypoxemia during air travel. Scientific poster

Phillips YY. Primary Blast Injury. Podium presentation at The Role of Advanced Conventional Weapons in Joint Peacekeeping and Ant-terrorism Operations, Defense Group Inc, Easton, MD, 29 Oct 1996.

Phillips YY. Blast Injuries. Podium presentation at 11th Conference on Military Medicine: Military Medicine in Complex Emergencies, Bethesda, MD, 14 March 1997.

Scientific posters presented at the International Scientific Assembly (American Thoracic Society) May 1997, San Francisco, CA:

Niven AS, Poropatich RK, Phillips YY, Parker JM, Torrington KG. High dose triamcinolone acetonide (TA) as induction therapy for pulmonary sarcoidosis.

Moore LK, Rayburn DB, Phillips YY and Fitzpatrick TM. Utilization of capnography as a non-volitional means of estimating airway obstruction.

Phillips YY. Blast injury. 1998 International Disaster Management Conference, February 18-19, 1998, Orlando, FL.

#### ABSTRACTS (1993-97):

Parker JM, Dillard TA, Phillips YY. Impact of using stated versus measured height on screening spirometry. *Am Rev Resp Dis* 1993; 147:A450

Roach JM, Argyros GJ, Hurwitz KM, Eliasson AE, Phillips YY. Eucapnic voluntary hyperventilation (EVH) as a bronchoprovocation technique in asthmatics: Comparison with Methacholine inhalation challenge. *Am Rev Resp Dis* 1993; 147:A258

Hurwitz KM, Roach JM, Argyros GJ, Eliasson AE, Phillips YY. Analysis of the refractory period after sequential testing with eucapnic voluntary hyperventilation and Methacholine inhalation challenge. *Am Rev Resp Dis* 1993; 147:A259

Kumke KM, Derderian SS, Hamm CK, Phillips YY, Rajagopal KR. The effect of Bupirone on sleep in stable asthmatics with severe air flow obstruction. *Chest* 1993; 104:51S

Weidner SF, Dillard TA, Barg BW, Mehm WJ, Phillips YY, et al. Effect of upright and supine posture on hypoxemia during air transport. *Chest* 1993; 104:90S

Eliasson AH, Poropatich RK, Howard RS, Phillips YY. PFT parameters in bronchoprovocation tests. *Am Rev Resp Dis* 1993; 147:A420.

Eliasson AH, Phillips YY, Torrington KG, Howard RS, Taylor YL, Dillard TA. The Grim Reaper: MD or RN? *Am J Resp and Crit Care Med* 1994; 149:A485.

Glass KL, Dillard TA, Phillips YY, Torrington KG. Pulse oximetry correction for smoking exposure. *Am J Resp and Crit Care Med* 1994; 149:A789.

Kumke KM, Derderian SS, Hamm CK, Phillips YY, Rajagopal KR. The effect of Bupirone on sleep in stable asthmatics with severe airflow obstruction. *Am J Resp and Crit Care Med* 1994; 149:A895.

Rayburn DB, Fitzpatrick TM, Lepler LS, Truwit JD and Phillips YY. Neural network analysis of sequential volume segments from expiratory CO<sub>2</sub> curves in the computation of FEV<sub>1</sub>/FVC ratio and predicted FEV<sub>1</sub>. Am J Resp and Crit Care Med 1994; 149:A938.

Berg BW, Dillard TA, Phillips YY, Weidner SF and Rajagopal KR. Hypoxia inhalation testing (HIT): application in COPD. Am J Resp and Crit Care Med 1994; 149:A1007.

Dillard TA, Moores LK, Bilello KL and Phillips YY. The pre-flight evaluation: a comparison of the hypoxic inhalation test with hypobaric exposure. Am J Resp and Crit Care Med 1994; 149:A1012.

Derderian SS, Dillard TA, Mehm WJ, Phillips YY and Rajagopal KR. Hemodynamic effects of altitude exposure to subjects with lung disease. Am J Resp and Crit Care Med 1994; 149:A1014.

Argyros GJ, Roach JM, Hurwitz KM, Eliasson AH and Phillips YY. The refractory period after eucapnic voluntary hyperventilation challenge and its effect on challenge technique. Am J Resp and Crit Care Med 1994; 149:A485.

Hurwitz KM, Eliasson AH, Argyros GJ, Phillips YY. Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma. Am J Resp and Crit Care Med 1995; 151:A402.

Argyros GJ, Roach JM, Hurwitz KM, Eliasson AH, Phillips YY. Eucapnic voluntary hyperventilation as a bronchoprovocation technique: development of a standardized ventilatory dosing schedule in asthmatics. Am J Resp and Crit Care Med 1995; 151:A402.

Dillard TA, Knutsen SW, Phillips YY, Berg BW, Mehm WJ, Criswell D. Prevention of altitude hypoxemia: comparison of an oxygen conserving device with nasal cannulae. Am J Resp and Crit Care Med 1995; 151:A784.

Parker JM, Dillard TA, Phillips YY. Arm span to height relationships in patients referred for screening spirometry. Am J Resp and Crit Care Med 1995; 151:A114.

Lawless NP, Dillard TA, Torrington KG, Phillips YY. Venturi devices for hypoxia inhalation testing. Chest 1995 108(3):140S.

Moores LK, Phillips YY, Bilello KM, Dillard TA. The effect of chronic oral diltiazem therapy on exercise capacity and response to hypoxic gas inhalation in severe COPD. Chest 1995 108(3):113S.

Moores LK, Phillips YY, Bilello KM, Dillard TA. The effect of acute and chronic diltiazem administration on pulmonary gas exchange and oxygen delivery in severe COPD. Chest 1995 108(3):196S.

Dillard TA, Knutson SW, Berg BW, Mehm WJ, Phillips YY. Accuracy of formulae for predicting hypoxemia during air travel. Am J Resp Crit Care Med 1996; 153:A455.

Niven AS, Poropatich RK, Phillips YY, Parker JM, Torrington KG. High dose triamcinolone acetonide (TA) as induction therapy for pulmonary sarcoidosis. Am J Resp Crit Care Med 1997; 155:A944.

Moores LK, Rayburn DB, Phillips YY and Fitzpatrick TM. Utilization of capnography as a non-volitional means of estimating airway obstruction. Am J Resp Crit Care Med 1997; 155:A595.

This is to acknowledge the receipt of your letter/application dated

5-12-98, and to inform you that the initial processing which includes an administrative review has been performed.

08-01738-02

There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 125704  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.

Sincerely,  
Licensing Assistance Team Leader

CURRICULUM VITAE

March 1998

NAME: Yancy Y Phillips, III

SSAN:

RANK: Colonel, Medical Corps

MOS: 60F9A

DOB:

POB:

SPOUSE:

CHILDREN:

HOME ADDRESS:

WORK ADDRESS: Department of Medicine  
Walter Reed Army Medical Center  
Washington, DC 20307-5001  
202-782-6205/2348  
FAX 202-782-6507  
E-Mail: COL\_YANCY\_PHILLIPS@WRAMC1-AMEDD.ARMY.MIL

EDUCATION:

- BS Chemical Engineering (High Honors), University of Delaware
- Master of Medical Science, CMDNJ-Rutgers Medical School
- Doctor of Medicine (Cum Laude), University of Alabama School of Medicine

POST-GRADUATE EDUCATION:

- 1976-77 Internal Medicine Internship, Tripler Army Med Center, Honolulu, HI
- 1977-79 Internal Medicine Residency, Tripler Army Medical Center
- 1980-83 Pulmonary Medicine Fellowship, Walter Reed Army Medical Center  
Washington, D.C.

1 5x6

**COVER SHEET FOR CORRESPONDENCE**  
**USE THIS COVER SHEET TO PROTECT ORIGINALS OF**  
**MULTI-PAGE CORRESPONDENCE**